Real-World Effectiveness and Tolerability of Indian Generic Semaglutide for Obesity: A Retrospective Observational Study from a Nationally Deployed Virtual Weight Management Programme
Archives of Endocrinology and Disorders · 12.08.2026 · 2 (2) · 1-10
DOI: 10.46889/aed.2026.2208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Endocrinology and Disorders, online erschienen am 12.08.2026. Verfasst von Darshit Jain und 3 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background and Aim: India’s semaglutide patent expired in March 2026, catalysing entry of more than 12 domestic generic manufacturers and reducing monthly treatment costs from ₹10,000-16,000 to under ₹2,000. Despite rapid nationwide adoption, particularly through digital health platforms, no independent post-marketing data exist for any Indian generic semaglutide formulation. This study addresses that gap. To evaluate the real-world effectiveness and tolerability of Indian generic semaglutide for obesity within a structured, physician-supervised national telehealth programme and to benchmark early outcomes against Phase 3 clinical trial data. Methods: Retrospective observational study using Electronic Medical Records (EMR) from the WeightWise programme (Tata 1mg Healthcare Solutions Pvt. Ltd., New Delhi), March-May 2026. Fifty (n=50) adults with obesity (BMI ≥27 kg/m²) initiating Indian generic semaglutide were identified; one patient was excluded (semaglutide prescribed for glycaemic management in type 2 diabetes, BMI below threshold). The final analytic cohort comprised 49 patients. Primary outcome: percentage body weight change from baseline to last follow-up. Secondary outcomes: proportion achieving ≥5% and ≥3% weight loss, rate of weight loss (kg/week), Gastrointestinal (GI) adverse event profile with severity grading and treatment discontinuation rate. Mean age was 38.5 ± 9.3 years (range 18-59; n=49); 57% male; mean baseline BMI 34.6 ± 5.2 kg/m²; mean baseline weight 96.6 ± 18.0 kg; mean treatment duration 3.9 ± 1.7 weeks (range 1-8). Mean body weight decreased by 2.94% ± 2.16% (95% CI: −3.54% to −2.34%; p
Zitieren
APA
Jain, D., Mangla, R., Gupta, M., & Chandra, M. (2026). Real-World Effectiveness and Tolerability of Indian Generic Semaglutide for Obesity: A Retrospective Observational Study from a Nationally Deployed Virtual Weight Management Programme. Archives of Endocrinology and Disorders, 2(2), 1-10. https://doi.org/10.46889/aed.2026.2208
Vancouver
Jain D, Mangla R, Gupta M, Chandra M. Real-World Effectiveness and Tolerability of Indian Generic Semaglutide for Obesity: A Retrospective Observational Study from a Nationally Deployed Virtual Weight Management Programme. Archives of Endocrinology and Disorders. 2026;2(2):1-10. doi:10.46889/aed.2026.2208
BibTeX
@article{Jain2026,
author = {Jain, Darshit and Mangla, Riya and Gupta, Muskan and Chandra, Mekhala},
title = {Real-World Effectiveness and Tolerability of Indian Generic Semaglutide for Obesity: A Retrospective Observational Study from a Nationally Deployed Virtual Weight Management Programme},
journal = {Archives of Endocrinology and Disorders},
year = {2026},
volume = {2},
number = {2},
pages = {1--10},
doi = {10.46889/aed.2026.2208}
}
EUVIMED